The company's strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies that are best positioned to conduct late-stage development and commercialization. Main programs include SkinJect™, a dissolvable microneedle patch delivering doxorubicin for basal cell carcinoma of the skin, and Teverelix, a long-acting GnRH antagonist for advanced prostate cancer and acute urinary retention relapse.
Cyborg Score Rationale
Q1 2026 Phase 2 SkinJect study showed positive dose-response and clearance activity in the 200‑µg cohort with 90 patients enrolled. However, the company reported a net loss of $9.0 million in Q1 2026 with substantial going-concern doubt, and faces significant liquidity constraints despite recent financing activities.
Top Insights
FDA cleared a Phase 2b Teverelix prostate cancer trial with royalty on future Teverelix sales reduced from ~4% to 2% (May 2026).
In 2026, company entered a definitive structured financing facility of up to $22 million with projected pro forma cash of about $30 million and operating cash runway of more than 24 months.
Strategic partnerships include collaboration with Gorlin Syndrome Alliance for compassionate access to SkinJect™ and a non-binding memorandum of understanding with Helix Nanotechnologies around thermostable infectious disease vaccines.
Company completed U.S. IPO on Nasdaq in November 2024, followed by $7.0 million public offering closing in June 2025 and $4.2 million Regulation A offering in March 2025.
Named Competitors
Mohs micrographic surgery and topical treatments — Standard basal cell carcinoma treatment options
GnRH antagonists in development — Competitive prostate cancer and hormone-related therapeutic options
Microneedle patch technology platforms — Novel drug delivery mechanisms for dermatology
Recent Developments
(May 2026) FDA cleared Phase 2b Teverelix prostate cancer trial; royalty rate reduced to 2%
(Q1 2026) Positive Phase 2 SkinJect dose-response data with 90 patients enrolled, $22M structured financing facility entered
(June 2025) Closed $7.0 million public offering
(March 2025) Closed $4.2 million Regulation A offering
(November 2024) Completed U.S. IPO on Nasdaq at $4.125 per unit
Open the full interactive Medicus Pharma Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.